Skip to main content
Premium Trial:

Request an Annual Quote

KineMed, Bristol-Myers Squibb Extend Collaboration on Alzheimer's Biomarkers

Premium

Proteomics firm KineMed and Bristol-Myers Squibb have extended their collaboration on Alzheimer's and other neurodegenerative diseases, KineMed said this week.

Under the extension, KineMed will grant BMS a non-exclusive license to its technology for the identification and characterization of Alzheimer's biomarkers in cerebrospinal fluid.

The companies didn't identify what biomarkers they would be investigating, but much of KineMed's past Alzheimer's work has focused on monitoring changes in microtubule dynamics by measuring related CSF biomarkers. The company's platform uses stable isotope labeling with mass spectrometry to measure the rates of change in various disease-related metabolic pathways.

In the June 2010 edition of Neuroscience KineMed scientists published a study tracking turnover levels of the protein tubulin in brain microtubule populations that suggested that changes in microtubule turnover can be used as a biomarker for the synaptic plasticity involved in memory formation.

Financial and other terms of the deal were not disclosed.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.